Citigroup Inc. Trims Position in Hologic, Inc. $HOLX

Citigroup Inc. decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,136,662 shares of the medical equipment provider’s stock after selling 170,451 shares during the period. Citigroup Inc. owned approximately 0.51% of Hologic worth $76,713,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Hologic by 10.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after purchasing an additional 3,520 shares during the period. Empowered Funds LLC lifted its stake in shares of Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after acquiring an additional 3,790 shares during the period. Ethic Inc. boosted its holdings in shares of Hologic by 127.5% in the second quarter. Ethic Inc. now owns 10,200 shares of the medical equipment provider’s stock valued at $663,000 after acquiring an additional 5,717 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Hologic by 9.4% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 581,479 shares of the medical equipment provider’s stock worth $37,889,000 after acquiring an additional 50,151 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $75.43 on Monday. The company has a 50-day simple moving average of $74.92 and a 200-day simple moving average of $71.91. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The company has a market cap of $16.84 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.47.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.87 EPS. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research report on Friday, November 21st. Argus cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.